NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

Search

DBV Technologies SA

Затворен

3.608 1.58

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.602

Максимум

3.642

Ключови измерители

By Trading Economics

Приходи

-12M

-45M

Продажби

3.4M

3.4M

Марж на печалбата

-1,323.179

Служители

117

EBITDA

-10M

-42M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-10.19% downside

Дивиденти

By Dow Jones

Следващи печалби

29.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

619M

1B

Предишно отваряне

2.03

Предишно затваряне

3.608

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

DBV Technologies SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.05.2026 г., 22:17 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4.05.2026 г., 23:47 ч. UTC

Печалби

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4.05.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Steady Amid Likely Technical Recovery -- Market Talk

4.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Regis: Jim Beyer To Be Chief Executive of Combined Company

4.05.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Shareholders to Own About 51% of Combined Company

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Board Unanimously Endorsed, Supported Deal

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Deal Unanimously Recommended by Vault Board

4.05.2026 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources to Acquire All Ordinary Shares in Vault

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources, Vault Minerals Agree to Merger of Equals

4.05.2026 г., 22:37 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4.05.2026 г., 22:26 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4.05.2026 г., 22:02 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4.05.2026 г., 22:00 ч. UTC

Пазарно говорене

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4.05.2026 г., 21:52 ч. UTC

Печалби

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Some Sectors More Affected Than Others>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4.05.2026 г., 21:49 ч. UTC

Печалби

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4.05.2026 г., 21:43 ч. UTC

Печалби

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4.05.2026 г., 21:41 ч. UTC

Печалби

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4.05.2026 г., 21:40 ч. UTC

Печалби

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Сравнение с други в отрасъла

Ценова промяна

DBV Technologies SA Прогноза

Ценова цел

By TipRanks

-10.19% надолу

12-месечна прогноза

Среден 3.26 EUR  -10.19%

Висок 5.5 EUR

Нисък 1.01 EUR

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за DBV Technologies SA през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

1

Купи

0

Задържане

1

Продай

Техническа оценка

By Trading Central

1.61 / 1.72Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
help-icon Live chat